Ariad suspends ponatinib sales

Area of Science:

• Oncology
• Cardiovascular Medicine
• Pharmacovigilance

Background:

• Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
• Ponatinib is a tyrosine kinase inhibitor used for CML treatment.
• Cardiovascular side effects have been a concern with tyrosine kinase inhibitors.

Purpose of the Study:

• To report the U.S. Food and Drug Administration's (FDA) action regarding ponatinib.
• To highlight the safety concerns leading to the suspension.
• To inform healthcare providers and patients about the temporary halt in sales and marketing.

Main Methods:

• Regulatory review of post-marketing safety data.
• Assessment of cardiovascular risk associated with ponatinib therapy.
• Communication of findings and actions to pharmaceutical companies and the public.

Main Results:

• The FDA identified serious cardiovascular side effects associated with ponatinib.
• Ariad Pharmaceuticals was requested to temporarily suspend sales and marketing of ponatinib.
• The suspension specifically targets the use of ponatinib in patients with chronic myeloid leukemia resistant to first-line therapy.

Conclusions:

• Concerns regarding serious cardiovascular side effects led to regulatory action on ponatinib.
• Temporary suspension of sales and marketing is a measure to mitigate patient risk.
• Alternative treatment strategies for resistant chronic myeloid leukemia need to be considered.